The company's first antineoplastic drug was INN Capecitabine. Its production was launched in 2015 at the Pharmasyntez-Nord plant. Currently, the company is manufacturing more than 40 names of anticancer drugs, 99% of which are included in the Vital and Essential Drugs List of the Ministry of Health of Russia.

In addition to antineoplastic drugs, the Pharmasyntez Group of Companies manufactures active pharmaceutical ingredients (APIs) for the production thereof. The production was established at BratskChemSyntez plant. Thus, the company provides full production cycle of anticancer drugs in Russia. This makes it possible to maintain a high level of product quality and availability, as well as ensures the country's independence from APIs supplies from abroad.

Furthermore, the company is constantly developing innovative antineoplastic drugs. One of the most promising drugs in the field of oncology is the innovative drug PF-114 (INN Vamotinib). It is intended for the treatment of Chronic Myeloid Leukemia (CML), which cannot be treated with the 1st or 2nd generation drugs. The drug is currently undergoing clinical trials.

Pharmasyntez is planning to further develop the direction of anticancer drugs and bring hope to a large number of patients for stable, affordable and effective anticancer therapy!